News
Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...
Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...
A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 ...
Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...
Novartis plans to spend $23 billion over the next five years to expand its manufacturing, research and technology presence in the U.S.
Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S.
The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...
Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...
Shares in Swiss drugmaker Novartis (NVS) were looking perkier today as it set out plans to invest $23 billion in U.S. manufacturing to beat the ...
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
Zacks Investment Research on MSN23h
Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains?Novartis NVS shares ended the last trading session 4% higher at $107.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback